A method for producing an .sup.225Ac solution includes a step (I) of irradiating a .sup.226Ra target with particles to generate two or more actinium radioisotopes (Ac) including at least .sup.225Ac, a step (II) of dissolving the .sup.226Ra target after the aforementioned step to obtain a solution (1), a step (III) of separating .sup.226Ra and Ac contained in the solution (1) to obtain a solution (2), a step (IV) of allowing Ac contained in the solution (2) other than .sup.225Ac to decay to obtain a solution (3), and a step (V) of separating Ra and Ac contained in the solution (3) to obtain a solution (4). The solution (4) is used to produce a medicine that contains, as an active ingredient, a conjugate between a chelating agent that has formed a complex with .sup.225Ac, and a targeting agent.

Kits for the preparation, synthesis, and delivery of compositions comprising a conjugate of a nucleoside analog, a chelator, and a label for use as imaging and therapeutic agents. The kits, as well as methods for their use, may be used in diagnosing, treating, or monitoring the progression of infectious diseases and/or symptoms or complications resulting from infection.

A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R.sup.0 is O or S. Each of R.sup.1a, R.sup.1b and R.sup.1c may be —CO.sub.2H, —SO.sub.2H, —SO.sub.3H, —PO.sub.2H, or —PO.sub.3H.sub.2, for example. R.sup.2 may be methylene or a derivative thereof, propylene or a derivative thereof, or a derivative of ethylene, optionally substituted. R.sup.3 is a linker. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions. ##STR00001##

The invention relates to the diagnostic uses of a conjugate comprising Omomyc or a functionally equivalent variant thereof and a detectable label for detecting lung cancer by pulmonary administration of the conjugate. The invention also relates to a method for detecting or imaging lung cancer using said conjugates, kits comprising said conjugates and conjugates comprising a contrast agent or an imaging agent.

The present invention aims to provide a carrier for drug delivery that selectively accumulates in the kidney in the body, and shows high biodegradability and drug releasability in the kidney. The present invention relates to a compound in which a carbonyl group of serine is linked directly or via a linker to terminal amino group of linear polylysine, compound carrier for delivery, and a medicament for the diagnosis, prophylaxis, or treatment of a renal disease, containing the carrier for drug delivery, and a drug bound to the carrier directly or via a linker or encapsulated therein.

The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging and therapeutic agents when bound to an appropriate metal centre, particularly for the imaging of tumours.

Methods and compositions are presented for use in diagnostic, imaging or targeting of therapeutic agents to treat cancer cells in metastases. such as where compositions and methods identify and employ peptides to selectively target cancer cells in metastases in mammals, both in vitro and in vivo.

The present invention relates to compositions and methods employing conjugates that include a self-assembly and disassembly (SADA) polypeptide and a binding domain. The present invention encompasses the recognition that conjugates with a SADA polypeptide have certain improved biological properties. SADA-conjugates are described, along with uses thereof (e.g., as therapeutic or diagnostic agents) and methods of manufacture.

The present disclosure relates to a method for labeling a biomolecule, a fluorescent dye, or a nanoparticle compound with a radioisotope, comprising: (a) providing a cyclooctyne compound represented by the following formula (I) comprising the biomolecule, the fluorescent dye, or the nanoparticle compound which is bound to a cyclooctyne moiety of the cyclooctyne compound; and (b) reacting the cyclooctyne compound of formula (I) with a quinone compound represented by the following formula (II) to give a biomolecule, a fluorescent dye, or a nanoparticle compound labeled with the radioisotope: ##STR00001## in formula (I), (Z is the biomolecule, the fluorescent dye, or the nanoparticle compound) ##STR00002## in formula (II), (b is 0 or an integer from 1 to 10; L is CH.sub.2, —COO—, or —CONH—; M is the radioisotope).

Provided herein are radiopharmaceutical compositions and uses thereof. The radiopharmaceutical compositions can comprise one or more stabilizing agents, an aqueous vehicle, and a conjugate that comprises a targeting ligand and a radionuclide bound to a metal chelator. The targeting ligand can be a small molecule compound or a peptide such as a monocyclic peptide. The targeting ligand can be configured to bind with a tumor target. The stabilizing agent can comprise a radiolysis stabilizer, a free metal chelator, and/or a pH stabilizer. Further provided herein are methods of preparing the radiopharmaceutical compositions and methods of treating cancer by administering the described radiopharmaceutical compositions.